Sipuleucel-T (Provenge) is a cell-based immunotherapy used to treat prostate cancer, combining prostatic acid phosphatase as a tumor rejection antigen presented by dendritic cells derived from a patient's monocytes.
Sipuleucel-T (Provenge) is een celgebaseerde immunotherapie voor de behandeling van prostaatkanker, die prostaat-specifiek alkalisch fosfatase (PAP) als tumor-afweerantigeen gebruikt, gepresenteerd door dendritische cellen afgeleid van de monocyten van een patiënt.
| Front | Cell-based immunotherapy used to treat prostate cancer that combined prostatic acid phosphatase as a tumor rejection antigen presented by dendritic cells derived from a patients monocytes |
|---|---|
| Back | sipuleucel-T Provenge |
Learn with these flashcards. Click next, previous, or up to navigate to more flashcards for this subject.
Next card: Rapamycin immunosuppressant drug blocks intracellular signaling pathways involving
Previous card: Inhibitor jak1 jak2 approved treatment myelofibrosis ruxolitinib
Up to card list: Janeway's Immunobiology 9th Edition Concept Flash Card